Early Detec­tion of Cancer Tests

The early detection tests are applied to indi­vid­u­als who have a high risk to develop can­cer, e.g., due to a fam­ily his­tory or genetic pre­dis­po­si­tion.

Due to their out­stand­ing diag­nos­tic pre­ci­sion, these tests have high poten­tial to be used for population-​wide screen­ing in the long ​term.

Our tests

  • enable erlier detection of pre-malignant lesions and cancer of the ovaries, fallopian tubes or the endometrium;

  • enable timely detec­tion of pri­mary and relapsed can­cer so that cura­tive mea­sures are still possible;

  • guide physi­cians select­ing the most appro­pri­ate ther­apy for each indi­vid­ual patient;

  • run on com­mer­cially avail­able analy­sis platforms.

The Immune Signature Tests are non-​invasive and are based on novel con­cepts ensur­ing unprece­dented sen­si­tiv­ity and speci­ficity. Proof-of-principle studies were performed for ovar­ian, breast and pan­cre­atic can­cer. The test prin­ci­ples allow application in other major types of cancer.

The LOC Test detects pre-malignant and malignant cells of ovarian cancer and endometrial cancer. The cells are collected from the uterine cavity with the specially designed and propietory Speiser Catheter.


Prognosis, Prediction and Monitoring Tests

These tests allow doctors to chose the most effi­cient treat­ment for their cancer patients. In addition, the tests will be designed to detect ther­apy fail­ures and/or can­cer recur­rence at an early statge which allows re-defining and adjusting the therapy in a timely manner.

The tests will be used to assess in real time whether the current therapy is effective or not. They will be applied at dif­fer­ent time points, namely before, dur­ing and after the ther­apy. When used in follow-​up sur­veil­lance after com­ple­tion of a  ther­apy, the monitoring tests even enable early detec­tion of a possible can­cer relapse.

Due to their non-​invasive nature and easy applic­a­bil­ity these blood tests rep­re­sent so-called LIQ­UID BIOP­SIES which— unlike tis­sue biop­sies — can the­o­ret­i­cally be per­formed an unlim­ited num­ber of times.

Our tests will be pro­vided in the form of test kits that con­tain all reagents nec­es­sary to per­form the tests on a com­mer­cially avail­able analy­sis platform. The LOC Test consists of the Speiser Catheter and mutation analysis performed in our service laboratory.


OncoLab Diagnostics GmbH
Mahlerstrasse 13
1010 Vienna

© OncoLab Diagnostics GmbH, 2017